Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study

European Journal of Cancer

Volumn 40, Issue 11, 2004, Pages 1713-1723

  Weijl, N I ^a   Elsendoorn, T J ^a   Lentjes, E G W M ^a   Hopman, G D ^a   Wipkink Bakker, A ^a   Zwinderman, A H ^a   Cleton, F J ^a   Osanto, S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antineoplastic agents; Antioxidants; Ascorbic acid; Cisplatin; Free radicals; Neoplasms; Oxidative stress; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BIOCHEMICAL MARKER; CISPLATIN; MALONALDEHYDE; SELENIUM; TRACE ELEMENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BEVERAGE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; FEMALE; HEAD AND NECK CANCER; HEARING; HUMAN; MALE; MELANOMA; NEPHROTOXICITY; OTOTOXICITY; OUTCOMES RESEARCH; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SARCOMA; TESTIS CANCER; UROGENITAL TRACT CANCER; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CISPLATIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; MICRONUTRIENTS; MIDDLE AGED; NEOPLASMS; SELENIUM; VITAMIN E;

EID: 3142610921     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.029     Document Type: Article

References (29)

1. Raber-Durlacher J.E., Weijl N.I., Abu Saris M., De Koning B., Zwinderman A.H., Osanto S. Oral mucositis in patients treated with chemotherapy for solid tumours: a retrospective analysis of 150 cases. Support Care Cancer. 8:2000;366-371
2. Osanto S., Bukman A., Van Hoek F., Sterk P.J., De Laat J.A., Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J. Clin. Oncol. 10:1992;574-579
3. Weijl N.I., Cleton F.J., Osanto S. Free radicals and antioxidants in chemotherapy induced toxicity. Cancer Treat. Rev. 23:1997;209-240
4. Speyer J.L., Green M.D., Zeleniuch-Jacquotte A., et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10:1992;117-127
5. Anonymous. Dexrazoxane for cardiac protection against doxorubicin. Med. Lett. 1995, 37, 110-111
6. Gandara D.R., Nahhas W.A., Adelson M.D., et al. Randomised placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J. Clin. Oncol. 13:1995;490-496
7. Weijl N.I., Hopman G.D., Wipkink-Bakker A., et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann. Oncol. 9:1998;1331-1337
8. Clemens M.R., Ladner C., Ehninger G., et al. Plasma vitamin E and β-carotene concentrations during radiochemotherapy preceding bone marrow transplantation. Am. J. Clin. Nutr. 51:1990;216-219
9. Faber M., Coudray C., Hida H., Mousseau M., Favier A. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin: a preliminary study. Biol. Trace Elem. Res. 47:1995;117-123
10. Weijl N.I., Rutten M.F.J., Zwinderman A.H., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J. Clin. Oncol. 18:2000;2169-2178
11. Moison R.M.W., De Beaufort A.J., Haasnoot A.A., Dubbelman T.M.A.R., Van Zoeren-Grobben D., Berger H.M. Uric acid and ascorbic acid redox ratios in plasma and tracheal aspirate of preterm babies with acute and chronic lung disease. Free Rad. Biol. Med. 23:1997;226-234
12. Lykkesfeldt J., Loft S., Nielsen J.B., Poulsen H.E. Ascorbic acid and dehydroascorbic acid as biomarkers of oxidative stress caused by smoking. Am. J. Clin. Nutr. 65:1997;959-963
13. Tangney C.C., McNair H.N., Driskell J.A. Quantitation of individual tocopherols in plasma, platelets, lipids and livers by high-performance liquid chromatography. J. Chromatogr. 224:1981;389-397
14. Draper H.H., Squires E., Mahmoodi H., Wu J., Agarwal S., Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Rad. Biol. Med. 15:1993;353-363
15. Thurnham D.I., Davis J.A., Crump B.J., Situnayake R.D., Davis M. The use of different lipids to express serum tocopherol: lipids ratios for the measurement of vitamin E status. Ann. Clin. Biochem. 23:1986;514-520
16. Pullar T., Feely M.P. Reporting compliance in clinical trials. Lancet. 336:1990;1252-1253. (letter)
17. Patient compliance in therapeutic trials. Lancet 1991, 337, 823-824 (editorial)
18. Levine A.M., Richardson J.L., Marks G., et al. Compliance with oral drug therapy in patients with hematologic malignancy. J. Clin. Oncol. 5:1987;1469-1476
19. Urquhart J. Patient compliance with crucial drug regimens: implications for prostate cancer. Eur. Urol. 29(suppl. 2):1996;124-131
20. Vitamin C. In: Flodin NW, editor. Pharmacology of micronutrients. New York, Alan R Liss, Inc, 1988, p. 201-244
21. Dorr R.T. A review of the modulation of cisplatin toxicities by chemoprotectants. Pinedo H.M., Schornagel J.H. Platinum and other metal coordination compounds in cancer chemotherapy 2. 1996;131-154 Plenum Press, New York and London
22. Trotti A. Toxicity antagonists in cancer therapy. Curr. Opin. Oncol. 9:1997;569-578
23. Hausheer F.H., Kanter P., Cao S., et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin. Oncol. 25:1998;584-589
24. Cascinu S., Cordelia L., Del Ferro E., Fonzoni M., Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomised double-blind placebo-controlled trial. J. Clin. Oncol. 13:1995;26-32
25. Parnis F.X., Coleman R.E., Harper P.G., et al. A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur. J. Cancer. 31A:1995;1721. (letter)
26. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomised control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14:1996;2101-2112
27. Planting A.S.T., Catimel G., Mulder P.H.M., et al. randomised study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann. Oncol. 10:1999;693-700
28. Sommer S., Thorling E.B., Jakobsen A., Steiness E., stergaard K. Can bismuth decrease the kidney toxic effect of cis-platinum. Eur. J. Cancer Clin. Oncol. 25:1989;1903-1904. (letter)
29. Pace A., Savarese A., Picardo M., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J. Clin. Oncol. 21:2003;927-931